Recent preclinical data on the efficacy of an ER degrading agent with a CDK4/6 inhibitor in ESR1-mutant breast cancer provides further rationale for this population, because improvements in TTP or OS could be caused by suppression of ESR1-mutant AI-resistant clones.27 This evidence concerns the gene CDK4 and breast cancer.